688185 康希诺
已收盘 03-28 15:00:01
资讯
新帖
简况
康希诺(688185)2月29日股东户数2.22万户,较上期减少1.54%
证券之星 · 03-28 17:13
康希诺(688185)2月29日股东户数2.22万户,较上期减少1.54%
康希诺2023年亏损扩大至近15亿元 新冠疫苗业务成主要拖累
每日经济新闻 · 03-28 13:59
康希诺2023年亏损扩大至近15亿元 新冠疫苗业务成主要拖累
图解康希诺年报:第四季度单季净利润同比减14.41%
证券之星 · 03-28 01:37
图解康希诺年报:第四季度单季净利润同比减14.41%
康希诺生物发布年度业绩 股东应占亏损14.83亿元 同比扩大63.04%
智通财经 · 03-27 23:38
康希诺生物发布年度业绩 股东应占亏损14.83亿元 同比扩大63.04%
康希诺发布2023年业绩报告 流脑疫苗商业化取得突破
证券时报网 · 03-27 23:09
康希诺发布2023年业绩报告 流脑疫苗商业化取得突破
康希诺2023年亏损近15亿元 流脑结合疫苗销售收入同比增长266%
证券时报·e公司 · 03-27 22:37
康希诺2023年亏损近15亿元 流脑结合疫苗销售收入同比增长266%
康希诺2023年度归属净利润约-14.83亿元
北京商报 · 03-27 21:59
康希诺2023年度归属净利润约-14.83亿元
康希诺:2023年营收3.57亿元,流脑疫苗产品销售收入增长266.39%至5.62亿元
财经网 · 03-27 21:17
康希诺:2023年营收3.57亿元,流脑疫苗产品销售收入增长266.39%至5.62亿元
康希诺:本次计提资产减值准备预计将减少公司2023年度合并报表利润总额约9.14亿元
每经网 · 03-27 20:52
康希诺:本次计提资产减值准备预计将减少公司2023年度合并报表利润总额约9.14亿元
康希诺:2023年净亏损14.83亿元
澎湃新闻 · 03-27 20:28
康希诺:2023年净亏损14.83亿元
康希诺生物2023年全年营收3.571亿元,上年同期10.34亿元;全年净亏损14.8亿元,上年同期净亏损9.09亿元
每日经济新闻 · 03-27 20:27
康希诺生物2023年全年营收3.571亿元,上年同期10.34亿元;全年净亏损14.8亿元,上年同期净亏损9.09亿元
康希诺03月26日遭主力抛售548万元 环比增加1667.74%
自选股智能写手 · 03-26 15:19
康希诺03月26日遭主力抛售548万元 环比增加1667.74%
北向资金3月25日净卖出康希诺5.14万股 连续3日减持
自选股智能写手 · 03-26 09:30
北向资金3月25日净卖出康希诺5.14万股 连续3日减持
三大全球盛会点燃科技创新赛道热情
银华基金 · 03-26 07:34
三大全球盛会点燃科技创新赛道热情
康希诺03月25日主力资金流出31万元 连续7日减仓
自选股智能写手 · 03-25
康希诺03月25日主力资金流出31万元 连续7日减仓
康希诺生物启动印尼Ⅲ期临床试验 拓展成人流脑疫苗市场
和讯网 · 03-25
康希诺生物启动印尼Ⅲ期临床试验 拓展成人流脑疫苗市场
康希诺03月21日主力资金流出90万元 连续5日减仓
自选股智能写手 · 03-21
康希诺03月21日主力资金流出90万元 连续5日减仓
康希诺:公司临床前的候选疫苗产品如有阶段性进展,会及时分享
证券之星 · 03-20
康希诺:公司临床前的候选疫苗产品如有阶段性进展,会及时分享
康希诺(06185.HK)吸附破伤风疫苗启动III期临床
阿斯达克财经 · 03-20
康希诺(06185.HK)吸附破伤风疫苗启动III期临床
康希诺(688185.SH):吸附破伤风疫苗启动III期临床试验并完成首例受试者入组
智通财经网 · 03-20
康希诺(688185.SH):吸附破伤风疫苗启动III期临床试验并完成首例受试者入组
加载更多
公司概况
公司名称:
康希诺生物股份公司
所属行业:
医药制造业
上市日期:
2020-08-13
主营业务:
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司主要产品为埃博拉病毒病疫苗、脑膜炎疫苗、百白破疫苗、肺炎疫苗、结核病疫苗、带状疱疹疫苗、新冠肺炎疫苗、腺病毒疫苗、脊髓灰质炎疫苗。公司获得了“天津瞪羚企业卓越创新奖”、“中国最具成长力科技创新型医药企业”、“天津市呼吸道细菌重组及结合疫苗企业重点实验室”等多项荣誉。
发行价格:
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":49.14,"timestamp":1711609201000,"preClose":48.89,"halted":0,"volume":1437569,"delay":0,"floatShares":114999999,"shares":247000000,"eps":-8.3089,"marketStatus":"已收盘","marketStatusCode":5,"change":0.25,"latestTime":"03-28 15:00:01","open":48.81,"high":49.95,"low":48.08,"amount":71038000,"amplitude":0.0382,"askPrice":49.15,"askSize":2,"bidPrice":49.14,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-8.3089,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1711675800000},"adr":0,"adjPreClose":48.89,"symbolType":"stock_kcb","openAndCloseTimeList":[[1711589400000,1711596600000],[1711602000000,1711609200000]],"highLimit":53.78,"lowLimit":44,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247449899,"pbRate":2.31,"roa":"--","roe":"--","epsLYR":-6.01,"committee":0.090909,"marketValue":12160000000,"floatMarketCap":5640000000,"peRate":-5.91414,"changeRate":0.0051,"turnoverRate":0.0125,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-04-02。","afterMarket":{"amount":0,"volume":0,"close":49.14,"buyVolume":0,"sellVolume":0,"time":1711611238379,"indexStatus":"已收盘 03-28 15:30:00","preClose":48.89}},"requestUrl":"/m/hq/s/688185","defaultTab":"news","newsList":[{"id":"2422515144","title":"康希诺(688185)2月29日股东户数2.22万户,较上期减少1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422515144","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422515144?lang=zh_cn&edition=full","pubTime":"2024-03-28 17:13","pubTimestamp":1711617224,"startTime":"0","endTime":"0","summary":"证券之星消息,近日康希诺披露,截至2024年2月29日公司股东户数为2.22万户,较12月31日减少347.0户,减幅为1.54%。在生物制品行业个股中,康希诺股东户数低于行业平均水平,截至2月29日,生物制品行业平均股东户数为3.36万户。从股价来看,2023年12月31日至2024年2月29日,康希诺区间跌幅为22.97%,在此期间股东户数减少347.0户,减幅为1.54%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032817160987bffb4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032817160987bffb4a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422138372","title":"康希诺2023年亏损扩大至近15亿元 新冠疫苗业务成主要拖累","url":"https://stock-news.laohu8.com/highlight/detail?id=2422138372","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422138372?lang=zh_cn&edition=full","pubTime":"2024-03-28 13:59","pubTimestamp":1711605540,"startTime":"0","endTime":"0","summary":"本次计提资产减值准备预计将减少公司2023年度合并报表利润总额约9.14亿元,减少净利润约9.14亿元,减少归属于上市公司股东的净利润约7.28亿元。该公告显示,2022年,上药康希诺亏损为8252.1万元,2023年扩大到亏损9.56亿元。但根据康希诺最新披露的年报,上药康希诺2023年的净亏损为9.78亿元。而这正是康希诺流脑疫苗和肺炎疫苗的目标人群。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281401077a4fb0c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403281401077a4fb0c5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422949721","title":"图解康希诺年报:第四季度单季净利润同比减14.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422949721","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2422949721?lang=zh_cn&edition=full","pubTime":"2024-03-28 01:37","pubTimestamp":1711561034,"startTime":"0","endTime":"0","summary":"证券之星消息,康希诺2023年年报显示,公司主营收入3.57亿元,同比下降65.49%;归母净利润-14.83亿元,同比下降63.04%;扣非净利润-16.11亿元,同比下降57.89%;其中2023年第四季度,公司单季度主营收入1.81亿元,同比下降44.54%;单季度归母净利润-4.98亿元,同比下降14.41%;单季度扣非净利润-5.32亿元,同比下降21.45%;负债率43.26%,投资收益7319.95万元,财务费用-5629.73万元,毛利率27.37%。财报数据概要请见下图:以上内容由证券之星根据公开信息整理,由算法生成,与本站立场无关。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032801430587bd260c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032801430587bd260c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422910945","title":"康希诺生物发布年度业绩 股东应占亏损14.83亿元 同比扩大63.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422910945","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2422910945?lang=zh_cn&edition=full","pubTime":"2024-03-27 23:38","pubTimestamp":1711553900,"startTime":"0","endTime":"0","summary":"康希诺生物发布截至2023年12月31日止的年度业绩,该集团期内取得收入3.45亿元,同比减少66.52%;股东应占亏损14.83亿元,同比扩大63.04%;每股基本亏损6.01元。公告称,收益减少主要因COVID-19疫苗产品需求减少及计提COVID-19疫苗产品退货约2.53亿元,对收入产生负面影响。研发开支由截至2022年12月31日止年度的约7.78亿元减少18.0%至截至2023年12月31日止年度的约6.38亿元,主要由于COVID-19疫苗产品的临床试验及测试费减少导致疫苗研发临床试验及测试费减少约2.49亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272355348b6a388b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272355348b6a388b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422911817","title":"康希诺发布2023年业绩报告 流脑疫苗商业化取得突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2422911817","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2422911817?lang=zh_cn&edition=full","pubTime":"2024-03-27 23:09","pubTimestamp":1711552196,"startTime":"0","endTime":"0","summary":"证券时报网讯,3月27日晚间,康希诺 发布经审计的2023年年报。2023年,得益于公司自主研发的两款流脑疫苗MCV4曼海欣和MCV2美奈喜商业化成功,康希诺流脑结合疫苗实现营业收入约5.62亿元,同比大幅增长约266.39%。公司表示,两款流脑疫苗商业化成功,意味着康希诺发展迎来新的增长引擎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032723100087bcc11f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032723100087bcc11f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422916427","title":"康希诺2023年亏损近15亿元 流脑结合疫苗销售收入同比增长266%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422916427","media":"证券时报·e公司","top":-1,"share":"https://www.laohu8.com/m/news/2422916427?lang=zh_cn&edition=full","pubTime":"2024-03-27 22:37","pubTimestamp":1711550220,"startTime":"0","endTime":"0","summary":"最后一点,康希诺为持续推广流脑疫苗产品增加营销活动推广,销售费用较同期增长。康希诺表示,报告期内,随着公司流脑疫苗产品商业化进程的推进,产品持续导入市场,流脑疫苗产品相关销售收入较去年同期大幅增长。2023年,康希诺两款流脑结合疫苗实现销售收入约5.62亿元,同比增长约266.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272237287a4f8ae3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272237287a4f8ae3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422191831","title":"康希诺2023年度归属净利润约-14.83亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422191831","media":"北京商报","top":-1,"share":"https://www.laohu8.com/m/news/2422191831?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:59","pubTimestamp":1711547940,"startTime":"0","endTime":"0","summary":"3月27日晚间,康希诺(688185)发布2023年年报显示,报告期内公司实现营业收入约为3.57亿元,同比下降65.49%;对应实现的归属净利润约为-14.83亿元,同比下降63.04%。资料显示,康希诺是一家致力于研发、生产和商业化符合中国及国际标准的创新型疫苗企业,已上市产品及在研产品管线涵盖预防脑膜炎、肺炎、百白破、新冠肺炎、埃博拉病毒病、带状疱疹、结核病等多个临床需求量较大的疫苗品种。(文章来源:北京商报)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722032087bc910c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032722032087bc910c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422202994","title":"康希诺:2023年营收3.57亿元,流脑疫苗产品销售收入增长266.39%至5.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422202994","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422202994?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:17","pubTimestamp":1711545447,"startTime":"0","endTime":"0","summary":"报告期内,公司主营业务收入为疫苗及相关产品销售收入,境内收入为3.42亿元,占主营业务收入比重为99.09%。同时,公司根据新冠疫苗产品的实际及预期退货情况,核算冲减报告期内相关收入2.53亿元及成本1.11亿元,并因报告期内新冠疫苗产量较低,相关产线产能利用率不足,集团将该部分冗余产能对应的固定成本2.51亿元计入营业成本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272118137a4f8678&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272118137a4f8678&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422994649","title":"康希诺:本次计提资产减值准备预计将减少公司2023年度合并报表利润总额约9.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422994649","media":"每经网","top":-1,"share":"https://www.laohu8.com/m/news/2422994649?lang=zh_cn&edition=full","pubTime":"2024-03-27 20:52","pubTimestamp":1711543951,"startTime":"0","endTime":"0","summary":"康希诺 (SH 688185,收盘价:48.89元)3月27日晚间发布公告称,本次计提资产减值准备预计将减少公司2023年度合并报表利润总额约9.14亿元,减少净利润约9.14亿元,减少归属于上市公司股东的净利润约7.28亿元。2022年1至12月份,康希诺的营业收入构成为: 生物医药 占比99.66%。康希诺的董事长、总经理均是XUEFENG YU(宇学峰),男,61岁,学历背景为博士。截至发稿,康希诺市值为121亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032721005387bc668b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032721005387bc668b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422995073","title":"康希诺:2023年净亏损14.83亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422995073","media":"澎湃新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422995073?lang=zh_cn&edition=full","pubTime":"2024-03-27 20:28","pubTimestamp":1711542480,"startTime":"0","endTime":"0","summary":"3月27日晚间,康希诺生物股份公司披露年报,2023年实现营业收入3.57亿元,同比下降65.49%;归属于上市公司股东的净利润为亏损14.83亿元,上年同期净亏损9.09亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272030308b69b05e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272030308b69b05e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422499577","title":"康希诺生物2023年全年营收3.571亿元,上年同期10.34亿元;全年净亏损14.8亿元,上年同期净亏损9.09亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2422499577","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2422499577?lang=zh_cn&edition=full","pubTime":"2024-03-27 20:27","pubTimestamp":1711542467,"startTime":"0","endTime":"0","summary":"每经AI快讯,3月27日,康希诺生物2023年全年营收3.571亿元,上年同期10.34亿元;全年净亏损14.8亿元,上年同期净亏损9.09亿元。每日经济新闻","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272028438b69af4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403272028438b69af4e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422523366","title":"康希诺03月26日遭主力抛售548万元 环比增加1667.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422523366","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422523366?lang=zh_cn&edition=full","pubTime":"2024-03-26 15:19","pubTimestamp":1711437557,"startTime":"0","endTime":"0","summary":"03月26日, 康希诺股价跌1.37%,报收50.50元,成交金额5676万元,换手率0.98%,振幅3.38%,量比0.89。康希诺今日主力资金净流出548万元,上一交易日主力净流出31万元,今日环比增加1667.74%。该股近5个交易日下跌10.56%,主力资金累计净流出1184万元;近20日主力资金累计净流出4094万元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032615392987b686ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032615392987b686ac&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422368877","title":"北向资金3月25日净卖出康希诺5.14万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2422368877","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422368877?lang=zh_cn&edition=full","pubTime":"2024-03-26 09:30","pubTimestamp":1711416632,"startTime":"0","endTime":"0","summary":"3月25日,北向资金减持康希诺5.14万股连续3日减持。截止当日收盘,沪股通共持有康希诺121.43万股,占流通股1.05%。沪股通减持金额前五个股分别为赛力斯、陕西煤业、紫金矿业、兖矿能源、浙江鼎力。康希诺近5个交易日下跌10.49%,沪股通累计减持29.48万股;近20个交易日下跌9.51%,沪股通累计减持4.14万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260936338b6336fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260936338b6336fd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422947505","title":"三大全球盛会点燃科技创新赛道热情","url":"https://stock-news.laohu8.com/highlight/detail?id=2422947505","media":"银华基金","top":-1,"share":"https://www.laohu8.com/m/news/2422947505?lang=zh_cn&edition=full","pubTime":"2024-03-26 07:34","pubTimestamp":1711409650,"startTime":"0","endTime":"0","summary":"近期,全球GPU技术大会、全球游戏开发者大会、全球光通信大会、三场全球性AI盛会接踵而至,或将进一步点燃科技创新赛道热情。更有甚者,大会上可能还会透露关于B100的下一代B200的信息,AI板块预期有望再度被点燃。3月27日,全球光通信大会将在美国加州圣地亚哥会展中心举行,是光通信领域规格最高、规模最大的国际性盛会。工具选择上,催化频出背景下,科技创新赛道有望迎来较强表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260730437a4ef559&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403260730437a4ef559&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422561365","title":"康希诺03月25日主力资金流出31万元 连续7日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2422561365","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422561365?lang=zh_cn&edition=full","pubTime":"2024-03-25 15:19","pubTimestamp":1711351154,"startTime":"0","endTime":"0","summary":"03月25日, 康希诺股价跌3.36%,报收51.20元,成交金额6947万元,换手率1.16%,振幅4.49%,量比1.02。康希诺今日主力资金净流出31万元,连续7日净流出,上一交易日主力净流出259万元,今日环比减少88.03%。该股近5个交易日下跌10.49%,主力资金累计净流出887万元;近20日主力资金累计净流出3819万元,其中净流出天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251539158b601080&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403251539158b601080&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422155719","title":"康希诺生物启动印尼Ⅲ期临床试验 拓展成人流脑疫苗市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2422155719","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2422155719?lang=zh_cn&edition=full","pubTime":"2024-03-25 14:02","pubTimestamp":1711346527,"startTime":"0","endTime":"0","summary":"康希诺生物四价流脑结合疫苗启动印尼Ⅲ期临床试验 近日,康希诺生物宣布其四价流脑结合疫苗在印度尼西亚启动Ⅲ期临床试验,并已完成首例受试者入组。本次Ⅲ期临床试验将拓展疫苗适用人群至成人,进一步丰富流脑疫苗市场。康希诺生物深化印尼合作 2022年11月,康希诺生物与印尼生物制药公司Etana签署合作协议,共同推进吸入疫苗技术和流脑疫苗的发展。共建人类卫生健康共同体 康希诺生物致力于创新疫苗技术,推动流脑疫苗创新与突破。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032514285587b1ba6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032514285587b1ba6a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421064413","title":"康希诺03月21日主力资金流出90万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2421064413","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421064413?lang=zh_cn&edition=full","pubTime":"2024-03-21 15:19","pubTimestamp":1711005566,"startTime":"0","endTime":"0","summary":"03月21日, 康希诺股价跌1.62%,报收55.40元,成交金额6530万元,换手率1.02%,振幅2.93%,量比0.77。康希诺今日主力资金净流出90万元,连续5日净流出,上一交易日主力净流出257万元,今日环比减少64.98%。该股近5个交易日下跌2.12%,主力资金累计净流出1552万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出3899万元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032115370587a0c9b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024032115370587a0c9b3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420712732","title":"康希诺:公司临床前的候选疫苗产品如有阶段性进展,会及时分享","url":"https://stock-news.laohu8.com/highlight/detail?id=2420712732","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2420712732?lang=zh_cn&edition=full","pubTime":"2024-03-20 19:01","pubTimestamp":1710932517,"startTime":"0","endTime":"0","summary":"康希诺董秘:尊敬的投资人您好,公司持续关注传染病领域临床需求量较大的疫苗品种,以发挥并拓展平台技术价值;产品管线、业务拓展、海外市场及相关合作方面,如有阶段性进展,会及时分享。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403201902178b4c3289&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403201902178b4c3289&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420132167","title":"康希诺(06185.HK)吸附破伤风疫苗启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2420132167","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2420132167?lang=zh_cn&edition=full","pubTime":"2024-03-20 17:38","pubTimestamp":1710927480,"startTime":"0","endTime":"0","summary":"康希诺生物(06185.HK) 公布,公司研发的吸附破伤风疫苗于近日正式启动III期临床试验,并完成首例受试者入组。该款疫苗主要用于非新生儿破伤风预防。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-03-20 16:25。)AASTOCKS新闻","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230120154912506_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230120154912506_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1335085/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2420790497","title":"康希诺(688185.SH):吸附破伤风疫苗启动III期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2420790497","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2420790497?lang=zh_cn&edition=full","pubTime":"2024-03-20 17:03","pubTimestamp":1710925380,"startTime":"0","endTime":"0","summary":"康希诺公告,公司的吸附破伤风疫苗于近日正式启动III期临床试验,并完成首例受试者入组。重症破伤风患者可并发喉痉挛、窒息、肺部感染和器官功能衰竭,病死率高达30%-50%,在无医疗干预的情况下病死率接近100%,是一种极为严重的潜在致命性疾病。公司研发的吸附破伤风疫苗采用无动物源培养基进行发酵,更加安全,已确定产业化规模工艺,工艺稳定。该款疫苗主要用于非新生儿破伤风预防,将进一步丰富公司产品管线,提升公司核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-20/doc-inanyitq8223635.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-03-20/doc-inanyitq8223635.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","stockEarnings":[{"period":"1week","weight":-0.113},{"period":"1month","weight":-0.1411},{"period":"3month","weight":-0.3406},{"period":"6month","weight":-0.3661},{"period":"1year","weight":-0.5722},{"period":"ytd","weight":-0.3406}],"companyName":"康希诺生物股份公司","boardCode":"AI0027","perCapita":"5159股","boardName":"医药制造业","registeredCapital":"24744万元","compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":-0.0016},{"period":"3month","weight":0.012},{"period":"6month","weight":-0.0321},{"period":"1year","weight":-0.0708},{"period":"ytd","weight":0.012}],"survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司主要产品为埃博拉病毒病疫苗、脑膜炎疫苗、百白破疫苗、肺炎疫苗、结核病疫苗、带状疱疹疫苗、新冠肺炎疫苗、腺病毒疫苗、脊髓灰质炎疫苗。公司获得了“天津瞪羚企业卓越创新奖”、“中国最具成长力科技创新型医药企业”、“天津市呼吸道细菌重组及结合疫苗企业重点实验室”等多项荣誉。","serverTime":1711648559401,"listedPrice":209.71,"stockholders":"22244人(较上一季度减少1.54%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}